GSK Plc - ADR GSK

Dividend Summary

The next GSK Plc - ADR dividend will go ex in 8 days for 45.18c and will be paid in 2 months.
The previous GSK Plc - ADR dividend was 45.01c and it went ex 3 months ago and it was paid 28 days ago.
There are typically 4 dividends per year (excluding specials).

Latest Dividends

Summary	Previous dividend	Next dividend
Status	Paid	Declared
Type	Quarterly	Quarterly
Per share	45.01c	45.18c
Declaration date	28 Jul 2026 (Tue)	28 Oct 2026 (Wed)
Ex-div date	14 Aug 2026 (Fri)	13 Nov 2026 (Fri)
Pay date	08 Oct 2026 (Thu)	07 Jan 2027 (Thu)

Enter the number of GSK Plc - ADR shares you hold and we'll calculate your dividend payments:

Previous Payment

$45.01

Paid on 08 Oct 2026 (Thu)

Next Payment

$45.18

Paid on 07 Jan 2027 (Thu)

Forecast Accuracy

98%

Our premium tools have predicted GSK Plc - ADR with 98% accuracy.

Try Premium

Dividend Yield Today

3.7%

The dividend yield is calculated by dividing the annual dividend payment by the prevailing share price

Free Email Notification

Add GSK Plc - ADR to receive free notifications when they declare their dividends.

Your account is set up to receive GSK Plc - ADR notifications.

Manage notifications

The table below shows the full dividend history for GSK Plc - ADR

Status	Type	Decl. date	Ex-div date	Pay date	Decl. Currency	Forecast amount	Decl. amount	Accuracy
Forecast	Quarterly	–	21 Feb 2031	10 Apr 2031	USD	Sign up	—
Forecast	Quarterly	–	15 Nov 2030	09 Jan 2031	USD	Sign up	—
Forecast	Quarterly	–	09 Aug 2030	10 Oct 2030	USD	Sign up	—
Forecast	Quarterly	–	17 May 2030	11 Jul 2030	USD	Sign up	—
Forecast	Quarterly	–	22 Feb 2030	11 Apr 2030	USD	Sign up	—
Forecast	Quarterly	–	16 Nov 2029	10 Jan 2030	USD	Sign up	—
Forecast	Quarterly	–	10 Aug 2029	11 Oct 2029	USD	Sign up	—
Forecast	Quarterly	–	18 May 2029	12 Jul 2029	USD	Sign up	—
Forecast	Quarterly	–	23 Feb 2029	12 Apr 2029	USD	Sign up	—
Forecast	Quarterly	–	17 Nov 2028	11 Jan 2029	USD	Sign up	—
Forecast	Quarterly	–	11 Aug 2028	12 Oct 2028	USD	Sign up	—
Forecast	Quarterly	–	19 May 2028	13 Jul 2028	USD	Sign up	—
Forecast	Quarterly	–	25 Feb 2028	13 Apr 2028	USD	Sign up	—
Forecast	Quarterly	–	19 Nov 2027	13 Jan 2028	USD	Sign up	—
Forecast	Quarterly	–	13 Aug 2027	07 Oct 2027	USD	Sign up	—
Forecast	Quarterly	–	21 May 2027	08 Jul 2027	USD	Sign up	—
Forecast	Quarterly	–	19 Feb 2027	08 Apr 2027	USD	Sign up	—
Declared	Quarterly	28 Oct 2026	13 Nov 2026	07 Jan 2027	USD	45.27c	45.18c	😄
Paid	Quarterly	28 Jul 2026	14 Aug 2026	08 Oct 2026	USD	45.23c	45.01c	😄
Paid	Quarterly	29 Apr 2026	15 May 2026	09 Jul 2026	USD	45.94c	45.5c	😄
Paid	Quarterly	04 Feb 2026	20 Feb 2026	09 Apr 2026	USD	49.32c	47.76c	😃
Paid	Quarterly	29 Oct 2025	14 Nov 2025	08 Jan 2026	USD	42.51c	43.31c	😃
Paid	Quarterly	–	15 Aug 2025	09 Oct 2025	USD	42.69c	43c	😄
Paid	Quarterly	01 May 2025	16 May 2025	10 Jul 2025	USD	42.89c	43.48c	😃
Paid	Quarterly	05 Feb 2025	21 Feb 2025	10 Apr 2025	USD	39.95c	40.76c	😃
Paid	Quarterly	30 Oct 2024	15 Nov 2024	09 Jan 2025	USD	39.02c	37.69c	😃
Paid	Quarterly	31 Jul 2024	16 Aug 2024	10 Oct 2024	USD	38.48c	39.28c	😃
Paid	Quarterly	01 May 2024	16 May 2024	11 Jul 2024	USD	37.53c	38.43c	😃
Paid	Quarterly	01 Feb 2024	22 Feb 2024	11 Apr 2024	USD	40.6c	40.49c	😄
Paid	Quarterly	01 Nov 2023	16 Nov 2023	11 Jan 2024	USD	33.99c	35.64c	😃
Paid	Quarterly	26 Jul 2023	17 Aug 2023	12 Oct 2023	USD	36.04c	34.35c	😃
Paid	Quarterly	26 Apr 2023	18 May 2023	13 Jul 2023	USD	34.71c	36.09c	😃
Paid	Quarterly	01 Feb 2023	23 Feb 2023	13 Apr 2023	USD	33.88c	34.19c	😄
Paid	Quarterly	02 Nov 2022	17 Nov 2022	12 Jan 2023	USD	—	33.48c
Paid	Quarterly	27 Jul 2022	18 Aug 2022	06 Oct 2022	USD	—	36.95c
Paid	Quarterly	02 May 2022	19 May 2022	01 Jul 2022	USD	—	34.14c
Paid	Quarterly	09 Feb 2022	24 Feb 2022	07 Apr 2022	USD	—	60.35c
Paid	Quarterly	28 Oct 2021	18 Nov 2021	13 Jan 2022	USD	—	51.68c
Paid	Quarterly	30 Jul 2021	19 Aug 2021	07 Oct 2021	USD	—	51.75c
Paid	Quarterly	04 May 2021	20 May 2021	08 Jul 2021	USD	—	52.62c
Paid	Quarterly	–	18 Feb 2021	08 Apr 2021	USD	—	63.67c
Paid	Quarterly	–	12 Nov 2020	14 Jan 2021	USD	—	51.67c
Paid	Quarterly	29 Jul 2020	13 Aug 2020	08 Oct 2020	USD	—	49.29c
Paid	Quarterly	29 Apr 2020	14 May 2020	09 Jul 2020	USD	—	47.39c
Paid	Quarterly	05 Feb 2020	20 Feb 2020	09 Apr 2020	USD	—	56.7c
Paid	Quarterly	–	14 Nov 2019	09 Jan 2020	USD	—	49.98c
Paid	Quarterly	–	08 Aug 2019	10 Oct 2019	USD	—	46.58c
Paid	Quarterly	–	16 May 2019	11 Jul 2019	USD	—	47.3c
Paid	Quarterly	07 Feb 2019	21 Feb 2019	11 Apr 2019	USD	—	60.17c
Paid	Quarterly	01 Nov 2018	15 Nov 2018	10 Jan 2019	USD	—	48.38c
Paid	Quarterly	25 Jul 2018	09 Aug 2018	11 Oct 2018	USD	—	49.56c
Paid	Quarterly	–	10 May 2018	12 Jul 2018	USD	—	50.33c
Paid	Quarterly	07 Feb 2018	22 Feb 2018	12 Apr 2018	USD	—	65.17c
Paid	Quarterly	–	09 Nov 2017	11 Jan 2018	USD	—	50.37c
Paid	Quarterly	–	09 Aug 2017	12 Oct 2017	USD	—	50.1c
Paid	Quarterly	26 Apr 2017	10 May 2017	13 Jul 2017	USD	—	49.04c
Paid	Quarterly	08 Feb 2017	22 Feb 2017	13 Apr 2017	USD	—	57.12c
Paid	Quarterly	–	02 Nov 2016	12 Jan 2017	USD	—	46.21c
Paid	Quarterly	27 Jul 2016	10 Aug 2016	13 Oct 2016	USD	—	46.65c
Paid	Quarterly	28 Apr 2016	11 May 2016	14 Jul 2016	USD	—	50.02c
Paid	Special	03 Feb 2016	17 Feb 2016	14 Apr 2016	USD	—	57.05c
Paid	Quarterly	03 Feb 2016	17 Feb 2016	14 Apr 2016	USD	—	65.61c
Paid	Quarterly	28 Oct 2015	10 Nov 2015	14 Jan 2016	USD	—	54.9c
Paid	Quarterly	29 Jul 2015	12 Aug 2015	01 Oct 2015	USD	—	57.69c
Paid	Quarterly	06 May 2015	13 May 2015	09 Jul 2015	USD	—	58.62c
Paid	Quarterly	04 Feb 2015	18 Feb 2015	09 Apr 2015	USD	—	69.52c
Paid	Quarterly	22 Oct 2014	05 Nov 2014	08 Jan 2015	USD	—	61.3c
Paid	Quarterly	23 Jul 2014	06 Aug 2014	02 Oct 2014	USD	—	64.82c
Paid	Quarterly	30 Apr 2014	14 May 2014	10 Jul 2014	USD	—	64c
Paid	Quarterly	05 Feb 2014	19 Feb 2014	10 Apr 2014	USD	—	74.96c
Paid	Quarterly	23 Oct 2013	13 Nov 2013	09 Jan 2014	USD	—	61.61c
Paid	Quarterly	24 Jul 2013	07 Aug 2013	03 Oct 2013	USD	—	55.32c
Paid	Quarterly	24 Apr 2013	08 May 2013	11 Jul 2013	USD	—	55.02c
Paid	Quarterly	06 Feb 2013	20 Feb 2013	11 Apr 2013	USD	—	68.95c
Paid	Quarterly	31 Oct 2012	14 Nov 2012	03 Jan 2013	USD	—	57.9c
Paid	Quarterly	–	08 Aug 2012	04 Oct 2012	USD	—	52.79c
Paid	Quarterly	–	09 May 2012	05 Jul 2012	USD	—	54.91c

Year	Amount	Change
2006	0.0c	—
2007	0.0c	 0%
2008	0.0c	 0%
2009	0.0c	 0%
2010	0.0c	 0%
2011	0.0c	 0%
2012	234.55c	 100%
2013	246.91c	 5.3%
2014	259.64c	 5.2%
2015	236.82c	 -8.8%
2016	200.0c	 -15.5%
2017	214.68c	 7.3%
2018	208.44c	 -2.9%
2019	200.56c	 -3.8%
2020	212.02c	 5.7%
2021	216.4c	 2.1%
2022	138.76c	 -35.9%
2023	146.57c	 5.6%
2024	156.16c	 6.5%
2025	177.55c	 13.7%
2026	Sign Up Required
2027	Sign Up Required
2028	Sign Up Required
2029	Sign Up Required
2030	Sign Up Required

GSK Plc Optimized Dividend Chart

The chart below shows the optimized dividends for this security over a rolling 12-month period.

Dividend Yield Today: 3.7%
Optimized Yield: Sign Up Required
52 Week High: 5.5% on 09 November 2025
52 Week Low: 3.2% on 20 February 2026
Next Ex-Div-Date Countdown: Sign Up Required

About GSK Plc

GlaxoSmithKline is a very large UK based pharmaceutical company with an excellent track record of delivering increased dividends to shareholders. In recent years it has been changing its strategy and reducing it's dependence on the pure pharmaceuticals business.

Sector: Pharmaceuticals & Biotechnology
Country: United States
Share Price: $51.15 (yesterday's closing price)
Shares in Issue: 2,023 million
Market Cap: $103.5bn
CADI The Consecutive Annual Dividend Increases - the number of years this company has been increasing its dividends: 3
Market Indices: none
Other listings: GSK Plc
Home Page URL: https://www.gsk.com/
Investor Relations URL: Sign Up Required
Dividend History URL: Sign Up Required
Financial Calendar URL: Sign Up Required

Matthew Riding

DividendMax Limited

https://cdn.dividendmax.com/assets/dividendmax-logo-69fb3a77a84cafdd3c25b46bcb112fc0bc5f3767d1c22ca1cbbae5f7cf9fb091.png

2026-10-28 09:25:25

GSK Announces Q3 Results The GSK plc Board has declared a third interim dividend for Q3 2026 of 17p per share (Q3 2025: 16p per share). The ex-dividend date is 12 November 2026 for ordinary shares, record date is 13 November 2026, and payment date of 7 January 2027 for GSK's Q3 2026 dividend.

28 Oct 2026

Matthew Riding

DividendMax Limited

https://cdn.dividendmax.com/assets/dividendmax-logo-69fb3a77a84cafdd3c25b46bcb112fc0bc5f3767d1c22ca1cbbae5f7cf9fb091.png

2026-02-04 09:04:33

GSK has declared a fourth interim dividend for Q4 2025 of 18p per share. Dividends:

04 Feb 2026

Matthew Riding

DividendMax Limited

https://cdn.dividendmax.com/assets/dividendmax-logo-69fb3a77a84cafdd3c25b46bcb112fc0bc5f3767d1c22ca1cbbae5f7cf9fb091.png

2025-04-30 07:04:11

GSK announce dividend declared of 16p for Q1 2025; 64p expected for full year 2025 GSK has declared a dividend for Q1 2025 of 16p per share. GSK's future dividend policy and guidance regarding the expected dividend pay-out in 2025 are provided on page 31.

30 Apr 2025

Matthew Riding

DividendMax Limited

https://cdn.dividendmax.com/assets/dividendmax-logo-69fb3a77a84cafdd3c25b46bcb112fc0bc5f3767d1c22ca1cbbae5f7cf9fb091.png

2025-02-05 10:29:11

GSK have announced a Q4 2024 dividend of 16p declared The GSK Plc Board has declared a fourth interim dividend for Q4 2024 of 16p per share (Q4 2023: 16p per share).

05 Feb 2025

Matthew Riding

DividendMax Limited

https://cdn.dividendmax.com/assets/dividendmax-logo-69fb3a77a84cafdd3c25b46bcb112fc0bc5f3767d1c22ca1cbbae5f7cf9fb091.png

2024-01-31 15:29:36

GSK Plc announce an increased dividend of 16p declared for Q4 2023 The GSK Board has declared a fourth interim dividend for 2023 of 16.00p per share (Q4 2022: 13.75p per share).

31 Jan 2024

Matthew Riding

DividendMax Limited

https://cdn.dividendmax.com/assets/dividendmax-logo-69fb3a77a84cafdd3c25b46bcb112fc0bc5f3767d1c22ca1cbbae5f7cf9fb091.png

2023-11-01 10:55:59

GSK Plc Q3 2023 dividend of 14p declared The GSK Plc Board has declared a third interim dividend for 2023 of 14p per share (Q3 2022: 13.75p per share).

01 Nov 2023

Matthew Riding

DividendMax Limited

https://cdn.dividendmax.com/assets/dividendmax-logo-69fb3a77a84cafdd3c25b46bcb112fc0bc5f3767d1c22ca1cbbae5f7cf9fb091.png

2023-02-01 08:44:19

GSK plc announce a 13.75p dividend declared for the Q4 2022 The GSK plc Board has declared a fourth dividend for 2022 of 13.75p per share (Q4 2021: 28.75p1 per share retrospectively adjusted) for the Share Consolidation.

01 Feb 2023

Matthew Riding

DividendMax Limited

https://cdn.dividendmax.com/assets/dividendmax-logo-69fb3a77a84cafdd3c25b46bcb112fc0bc5f3767d1c22ca1cbbae5f7cf9fb091.png

2022-07-27 10:32:54

GSK Plc has declared a second dividend for 2022 of 16.25p per share GSK Plc has declared a second dividend for 2022 of 16.25p per share, retrospectively adjusted for the Share Consolidation. The equivalent interim dividend receivable by ADR holders will be calculated based on the exchange rate on 4 October 2022. An annual fee of $0.03 per ADS (or $0.0075 per ADS per quarter) is charged by the Depositary. The ex-dividend date will be 18 August 2022, with a record date of 19 August 2022 and a payment date of 6 October 2022.

27 Jul 2022

Matthew Riding

DividendMax Limited

https://cdn.dividendmax.com/assets/dividendmax-logo-69fb3a77a84cafdd3c25b46bcb112fc0bc5f3767d1c22ca1cbbae5f7cf9fb091.png

2022-02-09 10:39:11

GlaxoSmithKline PLC declared an interim dividend of 23pence per share The GlaxoSmithKline PLC Board has declared a fourth interim dividend for 2021 of 23pence per share (Q4 2020: 23 pence per share).

09 Feb 2022

Matthew Riding

DividendMax Limited

https://cdn.dividendmax.com/assets/dividendmax-logo-69fb3a77a84cafdd3c25b46bcb112fc0bc5f3767d1c22ca1cbbae5f7cf9fb091.png

2020-10-07 00:48:42

GlaxoSmithkline 2015 full year results Summary · Group sales +6% CER on a reported basis and +1% CER pro-forma - Pharmaceuticals £14.2 billion, -7% (-1% pro-forma); Vaccines £3.7 billion, +19% (+3% pro-forma); Consumer Healthcare £6 billion, +44% (+6% pro-forma) · £2 billion of new product sales driven by HIV (Tivicay, Triumeq), Respiratory (Relvar/Breo, Anoro,Incruse) and Meningitis vaccines (Menveo, Bexsero) - Growing sales contribution: Q4 sales £682 million, (Q3: £591 million) - Nucala, a new biologic treatment for severe asthma, launched at the end of 2015 - New product sales now expected to reach £6 billion target up to two years earlier (2018 vs 2020) · Integration and restructuring programme on schedule - £1 billion incremental annual cost savings delivered in 2015 for costs of £1.9 billion - On track to deliver £3 billion of annual cost savings by end 2017 · 2015 core EPS 75.7p, -15% CER, ahead of financial guidance - Reflects short-term dilution from transaction partly offset by integration and restructuring benefits · 2015 total EPS 174.3p, +>100% CER - Reflects impact of transaction gains, partly offset by restructuring charges and revaluation of the contingent consideration relating to improved outlook for HIV business · 2016 core EPS percentage growth expected to reach double digits CER - If FX rates held at January average levels estimated impact of +5% on 2016 Sterling core EPS growth · 2015 ordinary dividend of 80p and special dividend of 20p confirmed - Special dividend to be paid alongside Q4 ordinary dividend in April 2016 - Continue to expect 80p full year dividend for 2016 and 2017 · New R&D portfolio of ~40 assets to drive long-term performance; multiple development milestones expected in 2016/2017 - Up to 10 regulatory filings include Shingrix (shingles vaccine), sirukumab (RA), Benlysta SC (lupus) and ICS/LABA/LAMA (COPD) - Up to 10 Phase lll starts include cabotegravir (HIV), daprodustat (anaemia) and Men ABCWY vaccine - Up to 20 Phase ll starts in Immuno-inflammation, Oncology, Respiratory and Infectious diseases - Estimated R&D rate of return maintained at 13%

04 Feb 2016